Metabolic dysfunction--associated steatohepatitis or MASH (formerly known as nonalcoholic steatohepatitis) is an inflammatory, liver-scarring disease that affects 1.5% to 6.5% of all U.S. adults. There are no approved pharmacological therapies for MASH and in the most severe case, the only recourse is liver transplantation.